HDAC2 as a target for developing anti-cancer drugs

Related Experiment Video

Updated: Aug 5, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.6K

Hyein Jo1, Kyeonghee Shim1, Han-Ul Kim1

  • 1Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 24341, Republic of Korea.

Computational and Structural Biotechnology Journal
|March 27, 2023
PubMed

Insights

Histone deacetylases (HDACs), specifically HDAC2, are crucial in regulating gene expression and chromatin structure. This review highlights HDAC2

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Epigenetics

Background:

  • Histone deacetylases (HDACs) regulate histone acetylation, a key epigenetic modification.
  • Aberrant histone acetylation/deacetylation is implicated in various diseases, including cancer.
  • HDAC2, a nuclear enzyme, plays a significant role in chromatin remodeling and gene transcription.

Purpose of the Study:

  • To review the roles of HDAC2 in tumorigenesis and the development of anti-cancer drug resistance.
  • To discuss the prognostic significance of HDAC2 in various cancers.
  • To explore the regulatory roles of microRNAs (miRNAs) on HDAC2 expression and its implications in cancer.

Main Methods:

  • Literature review of existing research on HDAC2.
  • Analysis of studies investigating HDAC2's function in cancer development.
  • Examination of research on miRNA-mediated regulation of HDAC2.

Main Results:

  • HDAC2 is implicated in promoting tumorigenesis and contributing to anti-cancer drug resistance.
  • HDAC2 serves as a potential prognostic biomarker for several types of cancer.
  • Specific miRNAs directly regulate HDAC2 expression, influencing cancer progression.

Conclusions:

  • HDAC2 is a critical regulator in cancer development and drug resistance.
  • HDAC2 represents a promising therapeutic target for novel anti-cancer drug development.
  • Understanding miRNA-HDAC2 interactions may offer new avenues for cancer treatment.
Keywords:
Anti-cancer drug resistanceAnti-cancer drugsCAGE, cancer associated geneDNMT1, DNA methyl transferase 1EMT, epithelial to mesenchymal transitionGC, gastric cancerHCC, hepatic cell carcinomaHDAC2, histone deacetylase 2Histone deacetylase 2NSCLC, non-small cell lung cancersPTEN, phosphatase and tensin homolog deleted on chromosome 10Prognostic markerTumorigenesismiRNAs, micro RNAs

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.6K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K